US Patent 11609236 Blood biomarkers for severe traumatic brain injuries

Disclosed herein is the use of plasma osteopontin (OPN) levels for diagnosing and predicting the severity and outcomes in traumatic brain injury (TBI), such as adult and pediatric TBI. The disclosed method can be used to diagnose TBI in any subject, such as pediatric, adult, and geriatric subjects. However, the method is particularly useful in pediatric subjects where current methods are insufficient. A particularly useful advantage of the disclosed methods is the ability to diagnose Abusive Head Trauma (AHT) in a pediatric subject.